Jordyn Sava

Major gaps in breast, cervical, and colorectal cancer screening use in federally qualified health centers in the United States were seen compared with overall screening rates nationally.

Finalized breast cancer screening recommendations from the United States Preventive Services Task Force suggest women aged 40 to 74 should get a mammogram every other year.

The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Here are the latest FDA approvals, designations, and decisions from April 2024.

A pivotal phase 2 study evaluating glecirasib for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer met its primary end point with an encouraging overall response rate.

The FDA issued a ‘safe to proceed’ for the investigational new drug application for PRAME TCR/IL-15 NK for relapsed or refractory myeloid malignancies.

Tisotumab vedotin is now an FDA-approved treatment for patients with recurrent or metastatic cervical cancer.

Lucia Masarova, MD, PhD, elaborated on the latest updates across myeloproliferative neoplasms, focusing on significant studies and emerging therapeutic approaches.

Trastuzumab-strf, a biosimilar of trastuzumab, has received FDA approval for treating HER2-overexpressing breast cancer and metastatic gastric cancer.

New data from the DESTINY-Breast06 trial indicate that trastuzumab deruxtecan could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer.

In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and head and neck cancers.

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.

In the interview with Targeted Oncology, Sanjay K. Juneja, MD, 2024 Oncology Icons honoree, discusses the transformative power of collaboration, technology, and compassionate care in shaping his career, as well as the future of cancer treatment.

Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.

Rhonda Henschel, MBA, discussed the challenges and considerations for community oncology practices looking to implement cellular therapy programs.

The phase 3 CONVERT study suggests that twice-daily radiotherapy remains the standard for limited-stage small cell lung cancer due to its effectiveness and lower associated toxicity compared to the once-daily approach.

The FDA approved adjuvant alectinib following tumor resection for the treatment of patients with ALK-positive non-small cell lung cancer.

Adjuvant pembrolizumab had an estimated 91.2% overall survival rate after 4 years compared with 86.0% for patients with clear-cell renal cell carcinoma who received a placebo.

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.

Three additional clinical trials will study nadofaragene firadenovec-vncg for the treatment of patients with non-muscle invasive bladder cancer.

A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received a PD-L1 inhibitor.

In an interview with Targeted Oncology, Sara Kerr, MD discussed the evolution of genomic testing for patients with cancer and highlighted the program used at Allina Health.

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.